UTHR vs. IONS, BMRN, MDGL, ALKS, ALNY, FOLD, SRPT, RDY, CTLT, and KRTX
Should you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Ionis Pharmaceuticals (IONS), BioMarin Pharmaceutical (BMRN), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), Alnylam Pharmaceuticals (ALNY), Amicus Therapeutics (FOLD), Sarepta Therapeutics (SRPT), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), and Karuna Therapeutics (KRTX). These companies are all part of the "pharmaceutical preparations" industry.
United Therapeutics (NASDAQ:UTHR) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, valuation and dividends.
Ionis Pharmaceuticals received 110 more outperform votes than United Therapeutics when rated by MarketBeat users. However, 61.66% of users gave United Therapeutics an outperform vote while only 60.09% of users gave Ionis Pharmaceuticals an outperform vote.
United Therapeutics has a net margin of 42.31% compared to Ionis Pharmaceuticals' net margin of -46.32%. United Therapeutics' return on equity of 17.72% beat Ionis Pharmaceuticals' return on equity.
94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 12.5% of United Therapeutics shares are owned by insiders. Comparatively, 2.7% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
United Therapeutics has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.
United Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500.
United Therapeutics currently has a consensus price target of $294.25, suggesting a potential upside of 25.83%. Ionis Pharmaceuticals has a consensus price target of $56.08, suggesting a potential upside of 34.83%. Given Ionis Pharmaceuticals' higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than United Therapeutics.
In the previous week, United Therapeutics had 19 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 23 mentions for United Therapeutics and 4 mentions for Ionis Pharmaceuticals. United Therapeutics' average media sentiment score of 0.62 beat Ionis Pharmaceuticals' score of 0.50 indicating that United Therapeutics is being referred to more favorably in the media.
Summary
United Therapeutics beats Ionis Pharmaceuticals on 14 of the 18 factors compared between the two stocks.
Get United Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
United Therapeutics Competitors List
Related Companies and Tools
